- Home
- ATRO vs ZYME Comparison
ATRO vs ZYME Comparison
Compare ATRO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRO
- ZYME
- Stock Information
- Founded
- ATRO 1968
- ZYME 2003
- Country
- ATRO United States
- ZYME United States
- Employees
- ATRO N/A
- ZYME N/A
- Industry
- ATRO Military/Government/Technical
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- ATRO Industrials
- ZYME Health Care
- Exchange
- ATRO Nasdaq
- ZYME Nasdaq
- Market Cap
- ATRO 634.4M
- ZYME 751.6M
- IPO Year
- ATRO N/A
- ZYME 2017
- Fundamental
- Price
- ATRO $16.54
- ZYME $15.39
- Analyst Decision
- ATRO Hold
- ZYME Buy
- Analyst Count
- ATRO 1
- ZYME 5
- Target Price
- ATRO $20.00
- ZYME $19.00
- AVG Volume (30 Days)
- ATRO 203.0K
- ZYME 572.6K
- Earning Date
- ATRO 11-06-2024
- ZYME 10-31-2024
- Dividend Yield
- ATRO N/A
- ZYME N/A
- EPS Growth
- ATRO N/A
- ZYME N/A
- EPS
- ATRO N/A
- ZYME N/A
- Revenue
- ATRO $782,178,000.00
- ZYME $62,199,000.00
- Revenue This Year
- ATRO $15.70
- ZYME $30.09
- Revenue Next Year
- ATRO $6.98
- ZYME N/A
- P/E Ratio
- ATRO N/A
- ZYME N/A
- Revenue Growth
- ATRO 19.95
- ZYME N/A
- 52 Week Low
- ATRO $14.58
- ZYME $7.80
- 52 Week High
- ATRO $23.74
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- ATRO 37.70
- ZYME 55.74
- Support Level
- ATRO $17.87
- ZYME $12.39
- Resistance Level
- ATRO $17.24
- ZYME $17.70
- Average True Range (ATR)
- ATRO 0.85
- ZYME 0.84
- MACD
- ATRO -0.18
- ZYME 0.10
- Stochastic Oscillator
- ATRO 13.61
- ZYME 56.50
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.